



Fresenius Medical Care

P R E S S R E L E A S E

December 20, 2005
Joachim Weith, Corporate Communications
Tel.: +49-6172-6082101
Fax: +49-6172-6082294
e-mail: pr-fmc@fmc-ag.de
www.fmc-ag.com

Share Conversion Offer Scheduled to Start in January 2006

Bad Homburg, Germany – December 20, 2005 - Fresenius Medical Care (“the Company”) (Frankfurt Stock Exchange: FME - ISIN: DE0005785802, FME3 - ISIN: DE0005785836) (NYSE: FMS, FMS-p), the world’s largest provider of Dialysis Products and Services, today announced that the share conversion offer is scheduled to start in January 2006 following the settlement of pending disputes initiated by minority shareholders. It is anticipated to offer all preference shareholders in a period of four weeks the opportunity to convert their preference shares into ordinary shares on a 1:1 basis accompanied by payment of a conversion premium of €9.75 per preference share to the Company. The share conversion and transformation of the legal form into a KGaA is expected to be completed during February 2006.

Ben Lipps, Chief Executive Officer of Fresenius Medical Care, commented: “I am pleased that we can continue with the implementation of these two important measures which fulfill the mandate of the extraordinary shareholder meeting on August 30, 2005. With these initiatives we have made a major step towards enhancing the attractiveness of our shares and in providing flexibility for future growth opportunities for the benefit of all stakeholders.”

Fresenius Medical Care AG is the world's largest, integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1,300,000 individuals worldwide. Through its network of approximately 1,670 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to approximately 130,400 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. For more information about Fresenius Medical Care visit the Company's website at www.fmc-ag.com.

The conversion offer may be made in the United States only by prospectus. A registration statement relating to the ordinary shares to be offered in the United States in the conversion offer for the outstanding preference shares of Fresenius Medical Care AG has been filed but has not yet been declared effective. The conversion offer has not yet commenced. If the conversion offer commences, each United States resident preference shareholder of Fresenius Medical Care AG should read the prospectus when it becomes available because it will contain important information about the conversion offer. When the registration statement is declared effective, Fresenius Medical Care preference shareholders can obtain the prospectus and other documents that are filed with the United States Securities and Exchange Commission's web site at <http://www.sec.gov>. Preference shareholders may also obtain copies of the prospectus and other documents filed with the Securities and Exchange Commission for free by contacting Fresenius Medical Care when the documents become available.

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG does not undertake any responsibility to update the forward-looking statements in this release.